Alamar Biosciences, Inc. (NASDAQ: ALMR) is a Healthcare company (Biotechnology) with a market capitalization of $2.1B. The Maz Rating grades it against the other companies in its sector.
Alamar Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $30.64, Alamar Biosciences, Inc. trades at 18.5x sales and 6.9x book value. Over the last twelve months it generated about $115M of revenue and a net loss of $58M. It runs a gross margin of 59.3%, an operating margin of -42.1% and a net margin of -48.2%. It shows return on equity of -78.7%, return on invested capital of -13.8% and a free cash flow yield of -3.2%. On the balance sheet: a debt-to-equity ratio of 0.14 and a current ratio of 9.49. Over the past 52 weeks the share price ranged from $18.85 to $39.61, with a beta of -6.18.
Alamar Biosciences, Inc. does not currently pay a dividend.
3 Wall Street analyst ratings cover the stock: 3 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.